Eli Lilly stock price target maintained at $825 by Cantor Fitzgerald

Eli Lilly's oral GLP-1 obesity drug, orforglipron, achieved 9% placebo-adjusted weight loss in Phase 3 trials, which is less effective than competing injectable and oral Semaglutide, prompting mixed analyst reactions. Cantor Fitzgerald reiterated an Overweight rating with an $825 price target, and Bernstein maintained an Outperform rating with a $1,000 target, while Berenberg downgraded LLY to Hold, citing a plateauing obesity market. Eli Lilly plans simultaneous global regulatory filings for orforglipron and has also launched an AI platform for drug discovery, indicating continued strategic focus on the sector despite competitive efficacy concerns.

Analysis

Eli Lilly's oral GLP-1 candidate, orforglipron, demonstrates a mixed profile following the publication of its Phase 3 ATTAIN-1 trial results. The drug achieved a 9% placebo-adjusted weight loss by week 72, a figure that is notably lower than the 12-13% efficacy demonstrated by competing injectable and oral Semaglutide. Furthermore, the data showed weight loss plateauing around the 40-week mark, a shorter duration than initially anticipated. This has led to a divergence in analyst sentiment; while Cantor Fitzgerald reiterated an Overweight rating ($825 PT) and Bernstein maintained an Outperform rating ($1,000 PT), Berenberg downgraded the stock from Buy to Hold ($830 PT), citing concerns of a "plateauing obesity market." Despite the competitive efficacy questions, the company is proceeding with plans for nearly simultaneous global regulatory filings and 14 analysts have revised earnings estimates upward, suggesting underlying confidence. However, the company has expressed caution about utilizing the FDA's new fast-track review process, which introduces uncertainty into the US approval timeline. Separately, Eli Lilly's launch of Lilly TuneLab, an AI platform for biotech leveraging proprietary data, signals a strategic investment in future drug discovery capabilities beyond its current pipeline.

Key Decisions for Investors

• Investors should closely monitor the competitive landscape, as orforglipron's 9% weight loss efficacy is lower than key competitors, making its potential market share highly dependent on pricing, safety profile, and the convenience of an oral formulation.
• The significant divergence in analyst price targets, from Berenberg's cautious $830 to Bernstein's bullish $1,000, highlights valuation uncertainty; positions should be managed with an awareness of both the drug's competitive challenges and the company's broader pipeline strength.
• Pay close attention to upcoming regulatory milestones for orforglipron, particularly the company's approach to the FDA, as any delays could impact revenue forecasts, while also factoring in the long-term potential of strategic initiatives like the Lilly TuneLab AI platform.